Mercer Global Advisors’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Mercer Global Advisors’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.9K	Buy	+150	New	+$6.69K	﹤0.01%	5219

Other funds holding BBC

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

MCM

Militia Capital Management Austin, Texas $3.37B AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

WAM

Worth Asset Management Dallas, Texas $313M AUM 37.93% 1-Year Est. Return

Operose Advisors Milwaukee, Wisconsin $517M AUM 24.68% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IFWM

Institute for Wealth Management Denver, Colorado $1.13B AUM 39.73% 1-Year Est. Return

Mercer Global Advisors's BBC Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Virtus Biotech Clinical Trials ETF (BBC) in Q2 2026: 150 shares worth $7.9K. The stake represents ﹤0.01% of the portfolio and ranks #5219 among its holdings.

14 funds tracked by Wall St. Rank hold BBC as of Q2 2026.

Mercer Global Advisors held 150 shares of Virtus Biotech Clinical Trials ETF worth $7.9K as of Q2 2026.
Virtus Biotech Clinical Trials ETF was a new Mercer Global Advisors position in Q2 2026.
Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5219 holding.
14 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.